CN Patent

CN1777613A — 奥氮平盐酸盐新的多晶型

Assigned to Egis Pharmaceuticals PLC · Expires 2006-05-24 · 20y expired

What this patent protects

本发明涉及2－甲基－4－(4－甲基哌嗪－1－基)－10氢－噻吩并[2，3－b]－[1，5]－苯并二氮杂盐酸盐的新晶型I，II和III，其制备方法和含有上述物质的药物组合物。所述新的多晶型用作精神病治疗的活性成分。

USPTO Abstract

本发明涉及2－甲基－4－(4－甲基哌嗪－1－基)－10氢－噻吩并[2，3－b]－[1，5]－苯并二氮杂盐酸盐的新晶型I，II和III，其制备方法和含有上述物质的药物组合物。所述新的多晶型用作精神病治疗的活性成分。

Drugs covered by this patent

remimazolam-besylate (REMIMAZOLAM BESYLATE)

Patent Metadata

Patent number: CN1777613A
Jurisdiction: CN
Classification: —
Expires: 2006-05-24
Drug substance claim: No
Drug product claim: No
Assignee: Egis Pharmaceuticals PLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.